Oric Pharmaceuticals announced Tuesday its plans to advance a PRC2 inhibitor into Phase 3 registrational trials for prostate cancer following results from a Phase 1b study. The company's shares dropped following the announcement, reflecting investor uncertainty about the drug development strategy.
The decision to move forward with Phase 3 trials represents a significant milestone for Oric's oncology pipeline, as registrational studies are designed to generate data for regulatory approval. PRC2 inhibitors target a protein complex involved in gene regulation that has been implicated in various cancers.